Takara Bio reports good safety for treatment of unresectable pancreactic cancer using oncolytic virus C-REV

C-REV (former name HF10) showed good safety and excellent anti-tumor effect in combination with chemotherapy on primary treatment of 6 Japanese patients with unresectable advanced pancreatic cancer. These are intermediate results of a Phase I study.

Takara Bio news release, January 15, 2018


Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny